Let’s talk!

No — and this is by design. SensAI Medical is a clinical decision support tool. It generates a protocol recommendation based on patient data and guideline synthesis, but no protocol is activated without explicit clinician review and sign-off.

The oncologist remains the decision-maker. SensAI removes the manual preparation burden — not the clinical judgement.

SensAI Medical synthesises across NCCN (National Comprehensive Cancer Network), NHS (National Health Service), and BCCA (BC Cancer Agency) protocols — alongside MOHAP and DHA guidelines specific to the UAE. Phase 2 and Phase 3 clinical trial data is also incorporated into the protocol generation engine.

The system is updated as guidelines evolve, so clinicians are always working from the most current evidence base.

• SensAI Medical is built to satisfy Cabinet Resolution No. 28/2020, which mandates DHA reporting and data traceability. Every protocol decision is logged with a full reasoning trace, generating audit-ready outputs automatically — eliminating the separate administrative burden of regulatory reporting.

  The system is deployable on AWS, GCP, or hybrid environments within UAE jurisdiction, ensuring patient data never leaves your infrastructure without explicit consent.

Liability remains with the treating clinician — as it does with all clinical decision support tools. SensAI Medical is a tool, not a decision-maker. The mandatory clinician sign-off step ensures that no protocol reaches a patient without a qualified oncologist having reviewed, adjusted if necessary, and approved it.

The full audit trail — including the AI's reasoning and any clinician modifications — is logged and legally defensible, which reduces rather than increases medico-legal exposure for institutions.

A typical pilot program runs 6–12 months, covering scoping, clinical validation, workflow integration, and governance framework setup. We work directly with the oncology department and hospital leadership — not just IT — to ensure the system fits your specific tumour board workflow.

No new infrastructure is required. SensAI Medical is designed to integrate into existing clinical environments with minimal disruption to current practice.

The core inputs are: cancer stage, receptor status (ER, PR, HER2), comorbidities, imaging results, and relevant patient history. This is the same data a clinician would use when manually compiling a protocol — SensAI simply processes it faster and more consistently.

The system is designed to work with data your clinical team already has. There is no requirement to collect additional information specifically for the AI.

Yes. SensAI Medical covers the full spectrum of breast cancer presentations — across all stages (I through IV) and receptor subtypes (ER+, PR+, HER2+, triple negative, and combinations). It supports the complete care pathway from initial diagnosis through post-treatment review and treatment modification.

The system is specifically trained on breast cancer protocols. It is not a general oncology tool — this specificity is what enables its depth and accuracy.

Each pilot includes: clinical validation of the protocol generation engine against your institution's existing cases, workflow integration into your tumour board process, and a governance framework aligned to your institution's compliance requirements — including DHA reporting under Cabinet Resolution No. 28/2020.

We also provide a clinical validation pack on request, which outlines the evidence base, accuracy benchmarks, and protocol alignment methodology before any commitment is made.

Yes — and this is one of SensAI Medical's core design principles. The system adapts its protocol recommendations based on facility type and resource context. Charity and public hospitals receive lowest-cost compliant pathways. Private hospitals benefit from reduced unnecessary testing and malpractice exposure.

The goal is to deliver the same gold-standard clinical outcome regardless of where the patient is treated — closing the 2.9% survival disparity currently observed across UAE regions.

Large vendors build general platforms. SensAI Medical is built specifically for breast cancer protocol generation in the UAE — with MOHAP and DHA alignment baked in from day one, not retrofitted. This specificity produces meaningfully higher guideline alignment scores and faster deployment timelines than general-purpose clinical AI tools.

SensAI Consulting also works as a deployment partner, not a software vendor. Every implementation is scoped and validated with the clinical team — not handed off after a licence sale.